GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Serina Therapeutics Inc (AMEX:SER) » Definitions » Change In Payables And Accrued Expense

Serina Therapeutics (Serina Therapeutics) Change In Payables And Accrued Expense : $0.99 Mil (TTM As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Serina Therapeutics Change In Payables And Accrued Expense?

Serina Therapeutics's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2024 was $0.81 Mil. It means Serina Therapeutics's Accounts Payable & Accrued Expense increased by $0.81 Mil from Jun. 2023 to Mar. 2024 .

Serina Therapeutics's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2022 was $-0.00 Mil. It means Serina Therapeutics's Accounts Payable & Accrued Expense declined by $0.00 Mil from Dec. 2021 to Dec. 2022 .

Serina Therapeutics Change In Payables And Accrued Expense Historical Data

The historical data trend for Serina Therapeutics's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Serina Therapeutics Change In Payables And Accrued Expense Chart

Serina Therapeutics Annual Data
Trend Dec21 Dec22
Change In Payables And Accrued Expense
-0.38 -

Serina Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Mar24
Change In Payables And Accrued Expense - 0.05 -0.06 0.18 0.81

Serina Therapeutics Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.99 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Serina Therapeutics Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Serina Therapeutics's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Serina Therapeutics (Serina Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Serina Therapeutics Inc (AMEX:SER) » Definitions » Change In Payables And Accrued Expense
Comparable Companies
Traded in Other Exchanges
2BO:Germany
Address
601 Genome Way, Suite 2001, Huntsville, AL, USA, 35806
Website
https://www.serinatherapeutics.com
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers.

Serina Therapeutics (Serina Therapeutics) Headlines

From GuruFocus

Enable Injections and Serina Therapeutics Announce Agreement to Develop SER-252 in Combination with enFuse� for Advanced Parkinson's Disease

By Marketwired • 05-15-2024